myDC/pDC in Stage III Melanoma Patients

Phase 1/2 Completed 30 enrolled Radboud University Medical Center

RandomizedParallel-groupOpen-labelTreatment

Summary

This is an interventional study to test the immunogenicity of combined adjuvant myDC and pDC vaccination versus adjuvant myDC or pDC vaccination alone in stage III melanoma patients.

Timeline

Start: 2015-09
Primary completion: 2021-09
Completion: 2021-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	myDC	Cell therapy	—	Other
Subject	pDC	Cell therapy	—	Other

myDC/pDC in Stage III Melanoma Patients

Summary

Timeline

Drugs

Indications